Loading...
Adjuvant therapy improves survival in patients with colorectal cancer. Standard therapy for stage III disease is 6 months of adjuvant 5-fluorouracil (5-FU) and oxaliplatin-based combination chemotherapy. In advanced colorectal cancer, the addition of the vascular endothelial growth factor ligand-targeted antibody bevacizumab improves antitumor response as well as disease-free survival (DFS) and overall survival.
Investigators now report the results of a multicenter, randomized, controlled, phase III trial of bevacizumab added to adjuvant chemotherapy for patients with stage II and III colon cancer. A total of 2710 patients received 6 months of modified FOLFOX6 (leucovorin and 5-FU at 400 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, and inf…